Vical Incorporated Share Price Nasdaq
Equities
US9256021042
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
03-15 | Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index | CI |
Sales 2022 | 6.94M 544M | Sales 2023 | 8.01M 627M | Capitalization | 5.25M 411M |
---|---|---|---|---|---|
Net income 2022 | -21M -1.65B | Net income 2023 | -5M -392M | EV / Sales 2022 | -0.59 x |
Net cash position 2022 | 8.63M 676M | Net cash position 2023 | 10.87M 852M | EV / Sales 2023 | -0.7 x |
P/E ratio 2022 |
-0.2
x | P/E ratio 2023 |
-0.83
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.4% |
Managers | Title | Age | Since |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 30/11/20 |
Nancy Seretta
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/15 |
Aaron Fox-Collis
AUD | Comptroller/Controller/Auditor | - | 30/06/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 30/11/20 |
1st Jan change | Capi. | |
---|---|---|
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |